Search peptides, terms, sources/

What's changed

Every change that affects meaning: new evidence, regulatory updates and corrections. Newest first.

  • PT-141 (Bremelanotide)

    UK status now cites an MHRA Products database search (no UK authorisation found). An unsourced statement about the reason was removed.

    Regulatory update
  • Liraglutide

    The safety source is now the official UK product information (Summary of Product Characteristics) for liraglutide's weight-management product, replacing an uncited monograph reference.

    Correction
  • Liraglutide

    The SCALE trial reference now carries its DOI and PubMed ID (Pi-Sunyer et al., NEJM 2015).

    Correction
  • Tirzepatide

    The SUMMIT trial reference now carries its DOI and PubMed ID (Packer et al., NEJM 2025).

    Correction
  • AOD-9604

    A finding based on an unidentifiable early-phase source was removed, as was an unsourced toxicology statement. The Phase IIb result is now cited to its 2005 conference record and a 2026 peer-reviewed review.

    Correction
  • Semax

    The 110-patient stroke finding is now cited to the correct study (Gusev et al., 2018). It was previously linked to a different 1997 study.

    Correction
  • Retatrutide

    Liver-fat figures corrected to the published 24-week values. Unsourced heart-rate and nausea figures removed. UK position now cites MHRA statements.

    Correction
  • Tirzepatide

    SURMOUNT-5 and SUMMIT figures checked against the primary papers and corrected.

    Evidence update
  • Cagrilintide

    Phase 2 trial size corrected to 706 randomised participants.

    Correction
  • Thymosin Alpha-1

    The TESTS sepsis trial is now cited to its primary paper (BMJ 2025).

    Evidence update
  • Sermorelin

    Removed an unsourced reason for the withdrawal of Geref. The FDA record says only that it was not withdrawn for safety or effectiveness reasons.

    Correction
  • BPC-157

    Removed an unsourced statement about how BPC-157 is sold in the UK. The same unsourced statement was removed from ten other profiles.

    Correction
  • BPC-157

    UK status now cites a dated MHRA database check. Sport status confirmed from WADA's own 2026 Prohibited List (S0).

    Regulatory update
  • TB-500

    Sport status confirmed from WADA's own 2026 Prohibited List (S2.3, thymosin beta-4 and its derivatives).

    Regulatory update
  • Kisspeptin

    UK status confirmed by a dated MHRA database check (no kisspeptin product found). WADA 2026 listing added.

    Regulatory update
  • AOD-9604

    UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.3).

    Regulatory update
  • CJC-1295

    UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.4).

    Regulatory update
  • Ipamorelin

    UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.4).

    Regulatory update
  • Sermorelin

    WADA 2026 listing added (S2.2.4).

    Regulatory update
  • Tesamorelin

    WADA 2026 listing added (S2.2.4).

    Regulatory update
  • Semax

    UK status now cites a dated MHRA database check.

    Regulatory update
  • Selank

    UK status now cites a dated MHRA database check.

    Regulatory update
  • Epithalon

    UK status now cites a dated MHRA database check.

    Regulatory update
  • TB-500

    Removed a venous-ulcer trial finding: it tested full-length thymosin beta-4, not TB-500, and cited a trial-design paper rather than the results. Some figures in it were not in the published results. The Phase 1 safety finding now cites the original study. The scoping-review finding now says plainly that direct TB-500 evidence is a single study.

    Correction
  • Teriparatide

    Teriparatide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Abaloparatide

    Abaloparatide added: 6 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Setmelanotide

    Setmelanotide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Afamelanotide

    Afamelanotide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Survodutide

    Survodutide added: 4 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Mazdutide

    Mazdutide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Elamipretide

    Elamipretide added: 6 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • MOTS-c

    MOTS-c added: 4 findings and 0 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • KPV

    KPV added: 5 findings and 1 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • GHRP-2

    GHRP-2 added: 6 findings and 1 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • GHRP-6

    GHRP-6 added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Hexarelin

    Hexarelin added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Thymosin beta-4

    Thymosin beta-4 added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.

    New profile
  • Semaglutide

    UK status re-checked against the official product information. Added two licensed uses that were missing: reducing major cardiovascular events in adults with heart disease and obesity or overweight, and weight management in adolescents aged 12 and over.

    Regulatory update
  • Oxytocin

    UK status re-checked against the official product information. All licensed obstetric uses are now listed.

    Regulatory update
  • Tirzepatide

    UK status re-checked against the official product information; no change to the licensed uses.

    Regulatory update
  • Liraglutide

    UK status re-checked against the official product information. Several generic liraglutide products are now listed; adolescent weight management added to the licensed uses.

    Regulatory update

Subscribe to this log as a feed: changes.xml. No sign-up, nothing collected.

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.